Results of Operations and Financial Condition. On May 12, 2026, the Company issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026. A copy of the press release, dated May 12, 2026, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it…

Results of Operations and Financial Condition. On March 3, 2026, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter and full year ended December 31, 2025. A copy of the press release dated March 3, 2026, is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934…

Results of Operations and Financial Condition. On November 4, 2025, the Company issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. A copy of the press release, dated November 4, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,…

Results of Operations and Financial Condition. On August 12, 2025, the Company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release, dated August 12, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor sha…

Chief Financial Officer — Rebecca Kuhn: Rebecca Kuhn resigned as Chief Financial Officer and transitioned to a Senior Strategic Advisor role with a successor appointed.

Entry into a Material Definitive Agreement. On June 4, 2025 (the “Closing Date”), NeuroPace, Inc. (the “Company”) entered into a credit, security and guaranty agreement (the “Credit Agreement”) by and among the Company, MidCap Funding IV Trust, as agent, MidCap Financial Trust, as term loan servicer and the financial institutions and other entities from time to time party thereto. The Credit Agreement provides for a first lien senior secured credit facility consisting of (i) a $60 million ter…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Termination of a Material Definitive Agreement. On June 4, 2025, concurrently with the Company’s entry into the Credit Agreement described in

Results of Operations and Financial Condition. On May 13, 2025, the Company issued a press release announcing its financial results for the fiscal quarter ended March 31, 2025. A copy of the press release, dated May 13, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it…

Results of Operations and Financial Condition. On March 4, 2025, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter and full year ended December 31, 2024. A copy of the press release dated March 4, 2025, is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934…

Other Events. On February 14, 2025, NeuroPace, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 6,500,000 shares of the Company’s common stock, par value $0.001 per share (the “Equity Offering”). The price to the public in the Equity Offering is $10.00 per share and t…

Entry into a Material Definitive Agreement. On February 13, 2025, NeuroPace, Inc. (the “Company” or “NeuroPace”) and KCK Ltd. (“KCK”) entered into a stock purchase agreement (the “Repurchase Agreement”) pursuant to which the Company has agreed to repurchase all of the shares of its common stock held by KCK in a privately negotiated transaction. The Company expects to fund the repurchase with a substantial portion of the gross proceeds from the sale of its common stock in the underwritten equi…

Results of Operations and Financial Condition. As previously announced, on January 28, 2025, NeuroPace, Inc. (the “Company”) hosted an in-person and virtual Investor Day, which highlighted the Company’s market, product and clinical development strategies and announced financial guidance for the year ending December 31, 2025. A replay will be posted to the Events section of the Company’s investor relations website. In its presentation, the Company also reaffirmed its preliminary financial resu…

Other Events. During the Investor Day presentation, the Company provided the following clinical and product development updates: Post-Approval Trial The Company announced primary effectiveness endpoint data at three years from the Company’s FDA-required, five-year post-approval, multicenter study in adults with focal epilepsy. Of the 324 patients in the trial across 32 participating centers, 271 patients completed three years in the study and 255 patients provided complete seizure data. The d…

Results of Operations and Financial Condition. On January 8, 2025, NeuroPace, Inc. (“NeuroPace”) issued a press release announcing certain preliminary financial results, including unaudited revenue for the fourth quarter and year ended December 31, 2024 and cash and short-term investments and shares of common stock outstanding as of December 31, 2024. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. These preliminary estimates are not a…

Director — Scott Huennekens: The company appointed a new director to fill an expanded board.

Results of Operations and Financial Condition. On November 12, 2024, the Company issued a press release announcing its financial results for the fiscal quarter ended September 30, 2024. A copy of the press release, dated November 12, 2024, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…

Results of Operations and Financial Condition. On August 13, 2024, the Company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2024. A copy of the press release, dated August 13, 2024, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor sha…

Entry into a Material Definitive Agreement. On May 2, 2024, NeuroPace, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Company’s existing Term Loan Agreement, dated as of September 24, 2020 (as amended from time to time, the “Loan Agreement”), with the lenders party to the Loan Agreement and CRG Servicing LLC, as administrative agent and collateral agent for the lenders. The Amendment extended the stated maturity date of the Loan Agreement by one year to September 30,…

Results of Operations and Financial Condition. On May 8, 2024, the Company issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024. A copy of the press release, dated May 8, 2024, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it b…

Results of Operations and Financial Condition. On March 5, 2024, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter and full year ended December 31, 2023. A copy of the press release dated March 5, 2024, is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934…

Chief Legal Officer and Corporate Secretary — Irina Ridley: Irina Ridley resigned from her role as Chief Legal Officer and Corporate Secretary.

Results of Operations and Financial Condition. On January 8, 2024, NeuroPace issued a press release announcing its preliminary unaudited revenue and cash balance for the fiscal quarter and year ended December 31, 2023, as well as providing a summary of business updates. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) is being furnished and shall not be deemed “fi…

Entry into a Material Definitive Agreement. On November 28, 2023 NeuroPace, Inc. entered into a collaboration agreement (“Agreement”) with Rapport Therapeutics, Inc. (“Rapport”), pursuant to which NeuroPace will provide certain site data for Rapport to use in targeting potential patients for their Phase 2a trial of their GAMA 8 Receptor-Associated Protein (“RAP”) compound and will then, upon patient consent, use its monitoring and data analytics capabilities to monitor RNS System patients tha…

Results of Operations and Financial Condition. On November 6, 2023, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023. A copy of the press release dated November 6, 2023, is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…